FTN Midwest Downgrades Barrier Therapeutics (BTRX) to Neutral
FTN Midwest downgrades Barrier Therapeutics (Nasdaq: BTRX) from Buy to Neutral.
Barrier Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the field of dermatology in the United States.
Related Categories
DowngradesStocks Mentioned
Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
